Novel Btk Inhibitor Heads to Phase III Trials in Chronic Lymphocytic Leukemia
1 Views
administrator
07/08/23
An experimental oral drug given once a day is drawing responses from about 70% of patients with relapsed chronic lymphocytic leukemia. Dr. Susan O'Brien explains why investigators are excited about PCI-32765 in an interview at the annual meeting of the American Society of Hematology
-
Category
Show more
Facebook Comments
No comments found